Axiom Biotechnologies appoints Sunny N. Stewart vice president, strategic development.SAN DIEGO--(BW HealthWire)--Feb. 13, 1997-- Former Genentech and IDEC IDEC Instituto Brasileiro de Defesa do Consumidor (Portugese: Brazilian Consumer Protection Agency) IDEC Information Design & End-User Computing IDEC Interior Design Educators Council, Inc. analyst/manager brings vast experience in fundraising, corporate partnering and intellectual property rights Management of privately held Axiom Biotechnologies Inc. Thursday announced that the company has appointed Sunny N. Stewart, M.B.A., J.D., as the company's vice president, strategic development. The former Genentech analyst/manager will be responsible for securing private investment capital, negotiating Axiom's strategic corporate partnership agreements and overseeing the expansion of the company's intellectual property portfolio. "Sunny's experience with Genentech as it grew from a mid-sized research organization to a multibillion-dollar pharmaceutical company will provide us with invaluable expertise as Axiom continues to grow its revenue base and secure additional corporate partnerships," said Pandi Veerapandian, Ph.D., president and chief scientific officer. "We are extremely pleased to have Sunny join our management team and we expect her to play an important role in the long-term growth and success of our company." Prior to joining Axiom Biotechnologies, Stewart worked as legal analyst for IDEC Pharmaceuticals (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :IDPH IDPH Illinois Department of Public Health IDPH Iowa Department of Public Health ) in San Diego San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. , where she was involved in both intellectual property issues and negotiating strategic alliances. During her tenure at IDEC she participated in completing more than seven strategic corporate alliances and more than 10 academic research collaborations. Prior to joining IDEC, Stewart served as litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. analyst/manager at Genentech Inc. (NYSE NYSE See: New York Stock Exchange :GNE GNE Gateway Network Element (data communications) GNE Game Neverending (MMORPG) GNE Gross National Expenditure GNE Game Networking Engine GNE Graphical Network Editor (Nortel) ), where she was directly involved in securing intellectual property licenses and negotiating worldwide technology license agreements. While at Genentech Stewart also was involved in negotiating the $300 million stock purchase agreement in which Hoffman-La Roche acquired a controlling interest controlling interest The ownership of a quantity of outstanding corporate stock sufficient to control the actions of the firm. Controlling interest often involves ownership of significantly less than 51% of a firm's outstanding stock because many owners fail in Genentech. During her 14-year tenure in biotechnology as an analyst and consultant, Stewart has participated in raising more than $150 million in public and private financing. In addition, she has been directly involved in establishing more than 20 corporate partnerships, both domestically and internationally, valued in total at more than $500 million. Stewart obtained an M.B.A. from the Wharton School, a J.D. from the University of Virginia and an M.S. from the Pasteur Institute The Pasteur Institute (French: Institut Pasteur) is a French non-profit private foundation dedicated to the study of biology, microorganisms, diseases and vaccines. . She is also actively participating in a variety of community service organizations and is a board member of Deaf Community Services of San Diego. Axiom Biotechnologies is a privately held biotechnology company committed to developing better, faster and smarter methods of drug discovery. The company has established a novel screening technology called High Throughput Pharmacological Screening (HT-PS) that allows the physiological responses of natural target cells to be monitored in the drug screening process. By providing non-exclusive access to its HT-PS technology and offering a navigational drug discovery database, called the Pharma Profile Database, Axiom's goal is to provide state-of-the-art information to pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. to accelerate their drug discovery efforts and to reduce overall costs associated with research and development. CONTACT: Axiom Biotechnologies Inc., San Diego Jim Linton, Ph.D., 619/455-4500 http://www.axiombio.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion